Fig. 1.

Translational potential of urate across neurologic diseases. Epidemiologic and laboratory evidence support a neuroprotective role of urate. Urate elevation has been employed in early clinical trials and has rapidly advanced to phase III testing in Parkinson’s disease (SURE-PD3 trial; NCT02642393; open to enrollment at the time of this publication). Enrollment for SURE-ALS2 is scheduled to begin in early 2017. ALS = amyotrophic lateral sclerosis; PD = Parkinson’s disease; SURE-ALS2 = safety of urate elevation in ALS, phase II; SURE-PD = safety of urate elevation in PD; SURE-PD3 = study of urate elevation in PD, phase III